Literature DB >> 3319290

Determination of cyclosporine concentrations with monoclonal antibodies.

H F Schran1, T G Rosano, A E Hassell, M A Pell.   

Abstract

We measured cyclosporine in whole blood from normal volunteers administered single oral doses of the drug and from two renal-transplant patients on immunosuppressive maintenance therapy, by liquid chromatography (I) and by radioimmunoassay with use of nonspecific polyclonal (II), specific monoclonal (III), and nonspecific monoclonal (IV) antibodies. Concentrations determined by III were equivalent to I, irrespective of cyclosporine dose, concentration, time after dose, or time after transplant. Concentrations determined by II and IV were consistently higher than those by I, owing to cross reactivity with metabolites. Ratios of values by II and IV to those by I increased from less than 1.5 to about 3-4 between 0.5 and 12 h after a single cyclosporine dose, owing to differences in rates of appearance and disappearance of cyclosporine and cross-reacting metabolites, though for the constant 12-h dose intervals in the two renal-transplant patients at steady state these ratios (most within the range 3-4) were relatively stable. Ratios of concentrations measured by IV to those by II (mean of 1.2 for single-dose data, most within the range of 1.2 to 1.5 at steady state) were unaffected by time after dose or time after transplant, suggesting that, despite certain cross-reactivity differences between the two nonspecific antibodies, results are proportional throughout therapy. We therefore propose that III and IV offer alternatives, respectively, to the currently used I and II for cyclosporine monitoring.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3319290

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  5 in total

1.  The management of heart transplant recipients treated with cyclosporine in Ireland: monitoring of cyclosporine concentrations in blood.

Authors:  F Kyne; S Maguire; D UaConaill; S O'Broin; E Clarke; S McCann; P Dervan; A E Wood
Journal:  Ir J Med Sci       Date:  1990 Sep-Dec       Impact factor: 1.568

Review 2.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

3.  Co-administration of ciprofloxacin and cyclosporin: lack of evidence for a pharmacokinetic interaction.

Authors:  K K Tan; A K Trull; S Shawket
Journal:  Br J Clin Pharmacol       Date:  1989-08       Impact factor: 4.335

Review 4.  A review of assay methods for cyclosporin. Clinical implications.

Authors:  K T Kivistö
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

5.  Adjusted-dose continuous-infusion cyclosporin A to prevent graft-versus-host disease following allogeneic bone marrow transplantation.

Authors:  K B Miller; D P Schenkein; R Comenzo; J K Erban; T Fogaren; C A Hirsch; E Berkman; A Rabson
Journal:  Ann Hematol       Date:  1994-01       Impact factor: 3.673

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.